Abstract: A method of increasing milk secretion of a predetermined milk component from a tissue culture comprising mammary epithelial cells (MECs) is provided. The method comprising admixing into a medium composition comprising the tissue culture, a biologically effective concentration of a composition selectably operable to increase the secretion of the predetermined components, the composition comprising at least one agent selected from the group consisting of oleic acid, beta-hydroxybutirate (BHBA) and a phenolic composition, wherein the agent is not an ethanol extract of P. lentiscus; and when the agent comprises oleic acid it comprises at least two of the agents.
Type:
Application
Filed:
September 14, 2023
Publication date:
December 28, 2023
Applicants:
Wilk Technologies International Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
Type:
Grant
Filed:
October 8, 2020
Date of Patent:
December 12, 2023
Assignees:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., University of Jerusalem Ltd.
Abstract: Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.
Type:
Grant
Filed:
September 30, 2021
Date of Patent:
December 5, 2023
Assignees:
University of Cincinnati, University of Texas System, The Hebrew University of Jerusalem
Inventors:
Nira Ben-Jonathan, Eric R. Hugo, Edward J. Merino, Abraham J. Domb, Armen N. Akopian
Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
November 21, 2023
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
Type:
Grant
Filed:
November 8, 2018
Date of Patent:
October 31, 2023
Assignees:
Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: Methods of determining the origin of cell free DNA (cfDNA), for detecting death of a cell type or tissue in a subject, for determining a cellular state of a cell as it died, and combinations thereof, are provided. As are computer program products for doing same.
Type:
Grant
Filed:
March 13, 2019
Date of Patent:
October 10, 2023
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: A system and method of non-invasive diagnosis of a condition in a subject may include obtaining, from a medical scanning device, a three-dimensional (3D) scan of the subject, said scan comprising a plurality of quantitative or semi-quantitative voxel values; segmenting the scan, to obtain a segmented region of interest (ROI) of the subject; performing a singular value decomposition (SVD) of the ROI, to determine at least one axis of the ROI in the SVD space; and analyzing the voxel values along the at least one axis, to diagnose a condition of the subject. Analysis of the voxel values may include calculating a quantitative function of voxel values along the at least one axis; comparing the calculated quantitative function to a reference quantitative function; and diagnosing or predicting a condition of the subject, based on the comparison.
Type:
Application
Filed:
June 22, 2021
Publication date:
October 5, 2023
Applicant:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: A spin-selective conduction structure comprises a crystal having a monolayer of metal atoms between two layers of chiral organic molecules. Each metal atom is coupled to two chiral organic molecules, one at each layer, wherein a chirality of organic molecules in one of the two layers is the same as a chirality of organic molecules in another one of the two layers.
Type:
Application
Filed:
March 8, 2021
Publication date:
September 21, 2023
Applicants:
Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventors:
Ehud GAZIT, Ron NAAMAN, Yossi PALTIEL, Shira YOCHELIS, Sharon GILEAD, Pandeeswar MAKAM, Amit Kumar MONDAL, Noam BROWN, Naama GOREN
Abstract: The present invention is directed to a method for determining a subject is afflicted with or having increased risk of developing an alpha-synuclein-associated disease or disorder, Parkinson's disease, or both. The method further includes administering to the subject determined as being afflicted with or having increased risk of developing an alpha-synuclein-associated disease or disorder a therapeutically effective amount of an agent characterized by being capable of decreasing signaling transduced by a member of PI4,5P2 PI3,4P2, PI3,5P2, PI3,4,5P3, PI3P, PI4P signal transduction pathway.
Type:
Application
Filed:
December 8, 2022
Publication date:
September 14, 2023
Applicant:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Inventors:
Ronit SHARON, Meir SCHECHTER, Suad ABD ALHADI
Abstract: A method of modifying a glycosylation pattern of a polypeptide-of-interest in a plant or plant cell is provided. The method comprising expressing in a plant or plant cell transformed to express at least one glycosidase in a subcellular compartment, a nucleic acid sequence encoding the polypeptide-of-interest, such that the at least one glycosidase and the polypeptide-of-interest are co-localized to the subcellular compartment of the plant or plant cell, thereby modifying the glycosylation pattern of the polypeptide-of-interest in the plant or plant cell.
Type:
Grant
Filed:
June 11, 2019
Date of Patent:
July 11, 2023
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
Inventors:
Oded Shoseyov, Helena Magrisso, Tzvi Zvirin, Amit Yaari, Zohar Katz
Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
Type:
Application
Filed:
December 20, 2022
Publication date:
July 6, 2023
Applicant:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventors:
David NAOR, Lora ESHKAR-SEBBAN, Keren-Or AMAR, Shmuel COHEN
Abstract: An electronic device element is described which is flexible, bendable or twistable without substantial degradation in optical or electrical properties. The electronic device element includes an optically transparent film constructed of a recombinant re-silin-CBD protein bound to cellulose nanocrystals (CNC). The recombinant resilin-CBD protein includes a Clostridium-derived cellulose-binding domain fused to resilin. The electronic device element may be a flexible display or flexible electronics element.
Type:
Application
Filed:
May 19, 2021
Publication date:
June 29, 2023
Applicants:
Smart Resilin Ltd., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LT
Inventors:
Oded Shoseyov, Liron Nesiel, Amir Rudich, Daniel Voignac
Abstract: Methods, compositions and kits for reducing renal tissue toxicity in a subject caused by a kidney damaging agent are provided. The methods comprise administering to the subject: (i) a kidney damaging agent; (ii) a PPARA activator; and (iii) an inhibitor of a cellular pathway selected from the group consisting of C/EBP, PPARG, ER stress, GLUT2 and SGLT1/2; or (i) a kidney damaging agent; (ii) a SGLT2 inhibitor; and (iii) a PPARA activator, a C/EBP inhibitor, a PPARG inhibitor, or an ER stress inhibitor.
Type:
Application
Filed:
February 20, 2023
Publication date:
June 29, 2023
Applicant:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: Disclosed are peptides that specifically bind to neutrophils and uses thereof for neutrophil-targeted delivery of drugs or diagnostic agents in medical conditions including cancer as well as infectious, inflammatory and autoimmune diseases or disorders.
Type:
Application
Filed:
December 27, 2022
Publication date:
June 29, 2023
Applicants:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
Abstract: Methods of treating coronavirus infection, or decreasing the risk of symptomatic infection, by administering a peroxisome proliferator-activated receptor alpha (PPARA) agonist or an inositol-requiring enzyme 1 (IRE1) pathway inhibitor are provided.
Type:
Application
Filed:
October 13, 2022
Publication date:
June 22, 2023
Applicant:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: The invention disclosed herein concerns a novel class of compounds suitable for the treatment of neurodegenerative diseases, such as Parkinson’s Disease.
Type:
Application
Filed:
February 22, 2023
Publication date:
June 22, 2023
Applicant:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: Provided is a composite of a CNT assembly including a plurality of carbon nanotubes (CNTs) and at least one metalcone material, the composite being tunable, by a vapor phase chemical modification, to adopt one or more collective properties selected from mechanical, chemical, physical or electrical properties.
Type:
Grant
Filed:
February 21, 2018
Date of Patent:
June 20, 2023
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: A system and method are presented, for monitoring and/or imaging of a sample. The system comprises: a light unit configured for illuminating the sample in at least two different wavelength ranges; a collection unit configured for collecting a light emitted from the sample in at least a third wavelength range and directing said emitted light towards at least one detector; and an activation unit configured for providing activation signal to selectively activate at least a portion of fluorescent substance in the sample; and a processing circuitry configured for operating the light unit to determine a selected temporal illumination profile of said at least two different wavelength ranges and for operating the activation unit for controllable activation.
Type:
Grant
Filed:
January 14, 2021
Date of Patent:
June 13, 2023
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.